Generated by AI
Axsome Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders. Its marketed products include Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness related to narcolepsy or obstructive sleep apnea, and Symbravo for the acute treatment of migraine. The company also maintains a neuroscience pipeline spanning additional neurological and psychiatric conditions, reflecting its emphasis on disorders with limited treatment options. Axsome Therapeutics Inc. plays a specialized role in the healthcare market by combining commercial products with ongoing clinical development in psychiatry, sleep medicine, pain, and migraine care. Based in New York, the company is positioned as a focused CNS innovator serving patients, physicians, and healthcare systems with therapies designed to address unmet medical needs.
WebsiteOne World Trade Center
New York, NY, 10007
United States
The latest articles about AXSM.
Axsome Therapeutics has delivered a very large 5 year share price gain, yet the stock has pulled back sharply in recent months. That mix of long term gains and recent weakness puts a simple question in front of you as an investor: is today's valuation justified by the sales the business is generating? Over the past 5 years, Axsome Therapeutics shares have returned about 237.2%, so a lot of optimism is already baked into the price that now needs to be weighed against the company's sales...
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 10's posts. Generated by AI.
A late-stage pipeline with 10 programs in development offers multiple growth catalysts beyond Auvelity's current commercial momentum.
Summary of Nov 2's posts. Generated by AI.
Investors talking about AXSM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.